Selank

Overview

Selank is a Russian peptide derived from the immune peptide tuftsin, marketed for both anti-anxiety and nootropic effects. It modulates the GABA and serotonin systems to lower anxiety while supporting cognition, reportedly without sedation or dependence. It is typically a research chemical requiring reconstitution and is most often used as an intranasal spray.

Expert Review

Dr. Dimitar Marinov, MD, PhD, a nutrition researcher, reviewed this page and noted that Selank appears safe and possibly effective when used intranasally to support calm and sharp thinking, while pointing out that nearly all the research has been conducted in Russia.

Our Verdict

The headline that grabs our attention is anti-anxiety effects mechanistically similar to benzodiazepines but without the addiction potential or cognitive dulling. Selank comes from tuftsin and acts as a positive allosteric modulator of GABA receptors. The major limitation is that the supporting research is essentially all Russian clinical data.

Evidence Quality

Human trials are moderate, drawn from Russian data, where Selank is approved for anxiety and neurasthenia. Animal evidence is strong, with clear anxiolytic effects and modulation of 34 inflammation-related genes. Community reports are strong, consistently describing reduced anxiety without sedation. The open question is whether Selank's immune-modulating action on those 34 inflammation genes has long-term consequences that short trials have not captured.

What the Research Shows

Selank is studied mainly for anxiety relief rather than cognitive stimulation. Research shows it changes the expression of GABA neurotransmission genes, pointing to a benzodiazepine-like mechanism. The Semax plus Selank combination is the most-discussed nootropic stack in community forums, pairing anti-anxiety and pro-cognitive effects. Intranasal dosing acts within 15-30 minutes in clinical protocols. Unlike benzodiazepines, there are no published reports of physical dependence, which is its main distinguishing feature.

Who Should Be Cautious

Because of its immune-modulating properties, people with autoimmune conditions should be careful, and anyone on immunosuppressive therapy should talk to their physician first.

What We Cannot Tell You

As with Semax, the clinical evidence is overwhelmingly Russian. Western regulators have not evaluated Selank, and no Phase III trials exist outside Russia.

Community Sentiment

Across 581 community reports, sentiment is 51% positive, 31% neutral, and 18% negative. The most cited benefits are anxiety reduction, cognitive enhancement, mood improvement, and calm; the most cited side effects are anxiety, elevated heart rate, hot flashes, and clammy skin. Benzodiazepine withdrawal also surfaces as a safety topic. Among 15 users who posted more than once over a median of 15 days, 4 grew more positive, 7 stayed about the same, and 4 grew more negative.

Dosage

The most common route is intranasal at 150-900 mcg per session, one to three times daily, with a 2.7 mg per day ceiling under Russian clinical protocols. It can also be injected subcutaneously at 100-300 mcg per day and is reported to be usable daily without tolerance buildup.

Effectiveness

Effects are often felt within hours, it reportedly keeps working without tolerance, and it is versatile across both anxiety and cognition.

Availability

Selank is sold as a research chemical by peptide suppliers, is an approved medication in Russia, and is frequently offered as a premade nasal spray.

Cited Research (Summarized)

Animal and in vitro studies report that Selank shifts the expression of 34 inflammation-related genes and similar immune-gene changes from its Gly-Pro fragment, alters GABAergic neurotransmission genes in a benzodiazepine-like way, improved attention, learning, and serotonin balance in rats exposed to antenatal hypoxia, and enhanced diazepam's anti-anxiety effect under chronic stress. Reviews describe it as a positive allosteric GABA modulator with anxiolytic, cognitive, and immune-stimulating benefits, and an observational study found it reduced adjustment-disorder symptoms. The consistent caveat is that this evidence has not been replicated outside Russia.